20Med is led by a skilled management team with a proven track record, backed by an experienced Supervisory Board. Our team consists of qualified researchers committed to make our company a key player in the RNA and DNA delivery market.
Chief Executive Officer
Michiel Lodder, PhD
Before joining 20Med Therapeutics in 2016, Michiel was responsible for corporate and business development at Lanthio Pharma which was acquired by MorphoSys AG in 2015. Before that he was CBO at Pepscan Therapeutics and prior to thatmanaging director of OctoPlus Inc, the Boston based US subsidiary of OctoPlus NV. Michiel holds a PhD in bioorganic chemistry from the University of Virginia and a MSc from Leiden University.
Chief Scientific Officer
Jaap Rip, PhD
Prior to joining 20Med Therapeutics, Jaap held leadership positions at Nanomi BV, Eyesiu Medicines BV and BBB Therapeutics. He is trained as Biologist at Wageningen University and obtained a PhD at the Amsterdam Medical Center. Jaap has a specific focus on the preclinical development, scale-up & manufacturing of complex injectable formulations with a strong background in polymer and lipid based (nano)particles for sustained release and targeted drug delivery.